On Thursday, Shares of Merck & Co., Inc. (NYSE:MRK) lost -0.03% to $60.11. The share price is trading in a range of $60.00 – 60.58. The stock exchanged hands with 10.10 million shares contrast to its average daily volume of 9.65 million shares.
Merck & Co. is working with Moffitt Cancer Center partner M2Gen on an program that backers hope leads to better treatment options for cancer patients.
Merck (NYSE: MRK) joined the Oncology Research Information Exchange Network Avatar Research Program. M2Gen manages the program.
ORIEN Avatar is “a precompetitive space created by M2Gen where pharma partners come together with ORIEN members [cancer centers throughout the United States] to generate data that will accelerate discovery and provide the foundation for matching cancer patients to the ‘best’ clinical trials for individual patients,” said Dr. Bill Dalton, founder and CEO of M2Gen in Tampa.
Merck is the third pharmaceutical program to join ORIEN Avatar, which has 15 cancer hospital members.
Celgene (NASDAQ: CELG) was a founding member in April and Takeda Pharmaceutical Company Limited (OTC: TKPYY) came on board in June.
As part of the program, patients who agree to take part in Moffitt’s Total Cancer Care program donate clinical and molecular data. Participating cancer researchers contribute the samples and disease information from their patients and receive molecular data plus a network of potential collaborators. Pharmaceutical companies contribute financial support and get access to de-identified patient data that can be used to develop new treatments. (Source: Tampa Bay Business Journal)
Merck & Co., Inc. (NYSE:MRK) have shown a high EPS growth of 41.50% in the last 5 years and has earnings growth of 21.80% yoy. Analysts have a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, “hold” within the 3 range, “sell” within the 4 range, and “strong sell” within the 5 range). The stock appeared -7.47% below its 52-week highs and is up 0.91% for the last five trades.
Shares of Rennova Health Inc (NASDAQ:RNVA) inclined 4.13% to $0.0858. The share price of the stock plunged -93.64% for the year.
Rennova Health, Inc. (RNVA), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, provides the following summary of its recent progress, in addition to commentary on its business strategy and milestones for 2017.
“We took a number of steps in 2016 to address challenges in the substance abuse testing sector, and we have begun to see the initial signs of success that will be instrumental to a return to top-line growth. Indeed, our fourth quarter was the best quarter for new sales in more than a year, and included several new clients, in addition to a number of returning clients,” said Seamus Lagan, Rennova’s chief executive officer. “We have diversified our business model and have secured in-network contracts with a number of third-party payers. We have moved from a concentration in substance abuse testing services in a single geographic location to providing a range of diagnostic services across the nation to an expanding and varied customer base.
“We expect that this continued expansion of our customer base and products, combined with an increasing number of contracts with various payers, will facilitate us to grow our 2017 revenues to levels that more closely resemble years before 2016,” Mr. Lagan concluded.
As formerly declared, the Company closed on an offering of preferred stock on December 20, 2016. The Company presently has 84,011,068 shares of common stock outstanding.
Analysts give RNVA a mean recommendation of 3.00. The company has dropped -64.04% in past 3 months and in the last five trades has moved down -1.38%. The stock has earnings growth of 68.10% yoy and showed a high EPS growth of 21.50% over the past five years. The stock’s price moved down its 200-day moving average of $0.23. The stock is presently trading down its SMA-50 of $0.10.